A Study of Oraxol® in Gastric Cancer Patients
The main objectives of this study are to determine the maximum tolerated dose (MTD) and recommend dose (RD) of Oraxol® in Phase I and to determine the objective response rate of Oraxol® in Phase II.
Advanced Metastatic Gastric Cancer|Recurrent Gastric Cancer
DRUG: Paclitaxel
Toxicity evaluation (safety evaluation), Toxicity will be evaluated by medical history, vital signs, physical examination and laboratory tests performed during the screening period (D-28 to D0) and treatment period based on NCI-CTCAE (version 3.0)., DLT will be assessed on 28days of 1 cycle|Overall response rate(ORR) evaluation, It is measured up to confirmation of tumor response(CR, PR)

Tumor response will be evaluated by RECIST v1.0., Response will be evaluated every Cycle 2(8weeks)
Administration Schedule: 1 cycle of Oraxol® is 28 days and Oraxol® is administrated twice a week, total 6 times per cycle (day 1,2,8,9,15 and 16).